New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
CEL-SCI announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. The news that Turkey has the 16th country to participate in the world's largest Phase III head and neck cancer trial of the firm's Leukocyte Interleukin, Injection follows last week's news that Sri Lanka's Ministry of Health had also cleared the company to commence patient enrollment in Sri Lanka. Similar clearances to conduct the Phase III study in the UK and Austria were announced in previous weeks and though it has becoming increasingly clear that CEL-SCI's expansion of the trial is finally going as planned, the valuation and share prices have yet to see a real impact.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:17 EDTCVMCEL-SCI reports enrolling 25 patients in February for Multikine study
CEL-SCI announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its phase III head and neck cancer trial for its investigational immunotherapy Multikine -- Leukocyte Interleukin, Injection. A total of 377 patients have been enrolled in study in head and neck cancer as of February 28. “During the month of February we also received clearance in the Philippines, Malaysia and Belarus to begin patient enrollment in those countries. This is expected to result in an even higher number of patients being enrolled in the study in March,” stated CEL-SCI CEO Geert Kersten. The goal is to enroll a total of 880 patients through approximately 100 clinical centers in about 25 countries by the end of 2015.
March 2, 2015
08:46 EDTCVMCEL-SCI cleared to enroll patients in trial in Belarus
Subscribe for More Information
February 19, 2015
08:06 EDTCVMCEL-SCI says Malaysia approves patient enrollment for Phase 3 Multikine trial
CEL-SCI announced the Ministry of Health Malaysia has cleared the company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine -- Leukocyte Interleukin, Injection -- in Malaysia. Malaysia is the 20th country to approve CEL-SCI’s Phase III trial, which now has over 350 patients enrolled. “Our plan called for having the trial cleared and conducted in a total of 21 countries, the United States plus 20 other countries. We are almost there,” stated CEO Geert Kersten. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use